NXTM stock: buy or sell?
June 28th, 2019
NxStage Medical, Inc., a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure.
Should I buy NXTM stock?You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. Following a trading plan helps to make decisions easier, quicker and with less hesitations. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
These 2 buy setups are elegible for NxStage Medical stock right now:
|New all-time high||Yes|
|New 52 week high||Yes|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is NxStage Medical stock a buy?
Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness.Unfortunately, we couldn't find any rating for NXTM stock for the last month.
NXTM stock analysis
NxStage Medical shares touched new all time highs again on June, marking to $30.00. Shares closed at $30.00 and stayed steady 0.00%.
After reaching all time highs on June, NxStage Medical stayed constant 0.00% on June to $30.00. Since price and SMA100d lines crossed up on January, NXTM climbed $1.72 (6.08%).
NxStage Medical shares topped new all time highs again this week, setting highs to $30.00. Shares closed at $30.00 and stayed steady 0.00% during the week. Late June was the fifth green week in a row.
Price pattern shows an uptrend with two rising tops and bottoms, and now finally trading above the $29.26 resistance. Since price and SMA20w lines crossed up late January, NXTM climbed $1.56 (5.49%).
NXTM stock price history
NXTM IPO was on January 4th, 2018 at $24.56 per share1. Since then, NXTM stock surged a 22.10%, with a yearly average of 22.10%. If you had invested $1,000 in NXTM stock in 2018, it would worth $221.00 today.
1: Adjusted price after possible price splits or reverse-splits.
NXTM stock historical price chart
NXTM stock reached all-time highs on June with a price of $30.00.
NXTM stock price targetNobody can reliably foresee how stock prices may evolve in the future. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. You should not follow the analysts' NXTM stock price predictions in the hope that they will be met as they may be wrong and not met. For the last month we have not detected any price forecast for NxStage Medical stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per ShareSince February, when NxStage Medical posted its last earnings report, it remained steady a tight 0.00%. Unfortunately, reported EPS is not yet available in our database.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2017, NxStage Medical annual turnover escalated an excellent 7.52% to $393.94 M USD from $366.38 marked in 2016. Instead, its income margin (compared to revenues) declined to -3.55%, that is $-13.99 million. To have an updated picture of the financial situation of NxStage Medical, we have calculated the trailing twelve month (TTM) sales and income figures. TTM values are the sum of the last 4 quarters and aproximate to an annual fiscal report ending in 2018-Q4 that can be compared to 2017 fiscal year results. Annual NxStage Medical TTM sales up to December 2018 were $322.39 and earnings were $-3.17 million USD. If we compare this TTM figures with the last reported annuality, we can esteem NxStage Medical business evolution since December 2017: Annual turnover up to December, compared to lastest yearly report, plunged a dreadful -18.16%. However, profit margin (net income/revenues) stepped up at -3.55%.
|2013||$263 M||-||$-18.56 M-7.0%||-|
|2014||$302 M||14.45%||$-23.95 M-7.9%||29.02%|
|2015||$336 M||11.48%||$-15.34 M-4.6%||-35.93%|
|2016||$366 M||9.00%||$-4.77 M-1.3%||-68.90%|
|2017||$394 M||7.52%||$-13.99 M-3.6%||193.27%|
|TTM||$322 M||-18.16%||$-3.17 M-1.0%||-77.37%|
Quarterly financial resultsNxStage Medical posted M in revenues for 2018-Q4, a -100.00% less compared to previous quarter. Reported quarter income marked M with a profit margin of . Profit margin remained constant a 0.00% compared to previous quarter when profit margin was 0.81%. When comparing revenues to same quarter last year, NxStage Medical sales marked a chilling drop down and plummed a -100.00%.
|2016-Q4||$93 M||-||$-1.60 M-1.7%||-|
|2017-Q1||$97 M||4.11%||$-1.19 M-1.2%||-25.63%|
|2017-Q2||$96 M||-0.63%||$-2.09 M-2.2%||75.63%|
|2017-Q3||$97 M||1.12%||$-8.45 M-8.7%||304.07%|
|2017-Q4||$104 M||6.48%||$-2.27 M-2.2%||-73.13%|
|2018-Q1||$107 M||3.57%||$-1.46 M-1.4%||-35.70%|
|2018-Q2||$107 M||-0.31%||$-2.59 M-2.4%||77.45%|
|2018-Q3||$108 M||1.08%||$0.88 M0.8%||-134.03%|
NxStage Medical ownershipWhen you are planning to invest in shares of a stock, it's worth to review its ownership structure.
NxStage Medical shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a of all shares.
For a better understanding, the next table shows ownership data compared to other related stocks:
|Market cap||$0.0 M|
|Total shares||0.0 M|
|Float shares||0.0 M|
|- Institutional holdings (%)||0.0%|
|- Insider holdings (%)||0.0%|
|Shares in short selling||0.0%|
|Friday, June 28th, 2019|
|Day range||$29.98 - $30.00|
|Average true range||$0.17|
|50d mov avg||$28.84|
|100d mov avg||$28.59|
|200d mov avg||$28.23|
NxStage Medical performanceStocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. We compared NxStage Medical against in the following table: